Health Benefits




Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.

The Cannabinoids Δ8THC, CBD, and HU-308 Act via Distinct Receptors to Reduce Corneal Pain and Inflammation

Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspar-tate-induced retinal neurotoxicity: involvement of peroxynitrite.

High Blood Pressure: The Leading Global Burden of Disease Risk Factor and the Need for Worldwide Prevention Programs

Obesity and cannabis use: results from 2 representative national surveys.


A systematic review of the antipsychotic properties of cannabidiol in humans.

Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer’s disease transgenic mice.

Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report

Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence

Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.

An Orally Active Cannabis Extract with High Content in Cannabidiol attenuates Chemically-induced In-testinal Inflammation and Hypermotility in the Mouse.

Cannabidiol, a Major NonΔPsychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts

Cannabinoids and the skeleton: from marijuana to reversal of bone loss.

Cannabinoid receptors and the regulation of bone mass.

The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content.


[174] Zachary Wilmer Reichenbach and Ron Schey, “Cannabinoids and GI Disorders: Endogenous and Exogenous,” Current Treatment Options in Gastroenterology 14, no. 4 (2016): 461–477. doi:10.1007/s11938-016-0110.

[175] Bradley E. Alger, “Getting High on the Endocannabinoid System,” Cerebrum: The Dana Forum on Brain Science (2013): 14.

[176] Yann LeStrat and Bernard Le Foll, “Obesity and Cannabis Use: Results From 2 Representative National Surveys,” American Journal of Epidemiology 174, no. 8 (2011): 929–933. doi:10.1093/aje/kwr200.

[177] L. Weiss, M. Zeira, S. Reich, M. Har-Noy, R. Mechoulam, S. Slavin, and R. Gallily, “Cannabidiol Low-ers Incidence of Diabetes in Non-obese Diabetic Mice,” Autoimmunity 39, no. 2 (2006): 143–151.

[178] Abigail Klein Leichman, “Cannabis Extract to Be Used to Treat Diabetes,” Israel 21c, April 21, 2015, -to-be-used-to-treat-diabetes/.

[179] H. J. Parray and J. W. Yun, “Cannabidiol Promotes Browning in 3T3-L1 Adipocytes,” Molecular and Cellular Biochemistry 416 (2016): 131–139.

[180] E. A. Penner, H. Buettner, and M. A. Mittleman, “Marijuana Use on Glucose, Insulin, and Insulin Resistance among US Adults,” American Journal of Medicine 126 (2013): 583–589.

[181] Sabine Steffens, Niels R. Veillard, Claire Arnaud, Graziano Pelli, Fabienne Burger, Christian Staub, Andreas Zimmer, Jean-Louis Frossard, and François Mach, “Low Dose Oral Cannabinoid Ther-apy Reduces Progression of Atherosclerosis in Mice,” Nature 434 (2005): 782–786.

[182] Francois Mach and Sabine Steffens, “The Role of the Endocannabinoid System in Ath-erosclerosis,” Journal of Neuroendocrinology 20, no. S1 (2008): 53–57. doi:10.1111/j.1365-2826.2008.01685.x.

[183] Mauro Maccarrone, Itai Bab, Tamás Bíró, Guy A. Cabral, Sudhansu K. Dey, Vincenzo Di Marzo, Justin C. Konje, George Kunos, Raphael Mechoulam, Pal Pacher, Keith A. Sharkey, and Andreas Zim-mer, “Endocannabinoid Signaling at the Periphery, 50 Years after THC,” Cell: Trends in Pharmacologi-cal Science 36, no. 5 (May 2015): 277–296.

[184] Sabine Steffens and Francois Mach, “Cannabinoid Receptors in Atherosclerosis,” Current Opin-ion in Lipidology 17, no. 5 (2006): 519–526. doi:10.1097/01.mol.0000245257.17764.b2.

[185] Ronen Durst, Haim Danenberg, Ruth Gallily, Raphael Mechoulam, Keren Meir, Etty Grad, Ronen Beeri, Thea Pugatsch, Elizabet Tarsish, and Chaim Lotan, “Cannabidiol, A Nonpsychoactive Cannabis Constituent, Protects against Myocardial Ischemic Reperfusion Injury,” American Journal of Physiology – Heart and Circulatory Physiology 293, no. 6 (2007): H3602–H3607. doi:10.1152/ajpheart.00098.2007.

[186] John C. Ashton and Paul F. Smith, “Cannabinoids and Cardiovascular Disease: The Out-look for Clinical Treatments,” Current Vascular Pharmacology 5, no. 3 (2007): 175–184. doi:10.2174/157016107781024109.

[187] Gabriella Aviello, Barbara Romano, Francesca Borrelli, Raffaele Capasso, Laura Gallo, Fabiana Piscitelli, Vincenzo Di Marzo, and Angelo A. Izzo, “Chemopreventive Effect of the Non-psychotropic Phytocannabinoid Cannabidiol on Experimental Colon Cancer,” Journal of Molecular Medicine 90, no. 8 (2012): 925–934. doi:10.1007/s00109-011-0856-x.

[188] “NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)- Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1Mice (Gavage Studies),” National Toxicology Program Tech-nical Report Series 446 (1996): 1–317.

[189] A. A. Thomas, L. P. Wallner, V. P. Quinn, J. Slezak, S. K. Van Den Eeden, G. W. Chien, and S. J. Jacobsen, “Association between Cannabis Use and the Risk of Bladder Cancer: Results from the Cali-fornia Men’s Health Study,” Urology 85, iss. 2 (2015): 388–393.

[190] Andras Bilkei-Gorzo, “The Endocannabinoid System in Normal and Pathological Brain Age-ing,” Philosophical Transactions of the Royal Society of London 367, no. 1607 (2012): 3326–3341. doi:10.1098/rstb.2011.0388.

[191] J. Fernández-Ruiz, O. Sagredo, M. R. Pazos, C. García, R. Pertwee, R. Mechoulam, and J. Martínez-Orgado, “Cannabidiol for Neurodegenerative Disorders: Important New Clinical Applica-tions for This Phytocannabinoid?” British Journal of Clinical Pharmacology 75, no. 2 (May 25, 2012): 323–333.

[192] Gary L. Wenk, “Animal Models of Alzheimer’s Disease,” Animal Models of Neurological Disease I (1992): 29–64, doi:10.1385/0-89603-208-6:29.

[193] N. M. Kogan, E. Melamed, E. Wasserman, B. Raphael, A. Breuer, K. S. Stok, R. Sondergaard, A. V. Escudero, S. Baraghithy, M. Attar-Namdar, S. Friedlander-Barenboim, N. Mathavan, H. Isaksson, R. Mechoulam, R. Müller, A. Bajayo, Y. Gabet, and I. Bab, “Cannabidiol, A Major Nonpsychotropic Canna-bis Constituent, Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts,” Journal of Mineral and Bone Research 30, no. 10 (October 2015): 1905–1913.

[194] A. J. Hampson, M. Grimaldi, J. Axelrod, and D. Wink, “Cannabidiol and (−)∆9-Tetrahydrocan-nabinol Are Neuroprotective Antioxidants,” Proceedings of the National Academy of Sciences of the United States of America 95, no. 14 (1998): 8268–8273.

[195] N. Dobrosi, B. I. Toth, G. Nagy, A. Dozsa, T. Geczy, L. Nagy, C. C. Zouboulis, R. Paus, L. Kovacs, and T. Biro, “Endocannabinoids Enhance Lipid Synthesis and Apoptosis of Human Sebocytes via Cannabinoid Receptor-2-Mediated Signaling,” The FASEB Journal 22, no. 10 (2008): 3685– 3695. doi:10.1096/fj.0604877.

[238] G. A. Grierson, “The Hemp Plant in Sanskrit and Hindi Literature,” Indian Antiquary (September 1894): 260–262.

[239] A. R. Schier, N. P. Ribeiro, A. C. Silva, J. E. Hallak, J. A. Crippa, A. E. Nardi, and A. W. Zuardi, “Can-nabidiol, a Cannabis sativa Constituent, As an Anxiolytic Drug,” Revista Brasileira de Psiquiatri 34, suppl. 1 (2012): S104–S110. PubMed PMID: 22729452.

[240] R. J. Bluett, J. C. Gamble-George, D. J. Hermanson, N. D. Hartley, L. J. Marnett, and S. Patel, “Central Anandamide Defciency Predicts StressInduced Anxiety: Behavioral Reversal through Endo-cannabinoid Augmentation,” Translational Psychiatry 8, no. 4 (2014): e408. doi:10.1038/ tp.2014.53.

[241] A. C. Campos, Z. Ortega, J. Palazuelos, M. V. Fogaça, D. C. Aguiar, J. Díaz-Alonso, S. Ortega-Guti-érrez, H. Vázquez-Villa, F. A. Moreira, M. Guzmán, I. Galve-Roperh, and F. S. Guimarães, “The Anxiolytic Effect of Cannabidiol on Chronically Stressed Mice Depends on Hippocampal Neurogenesis: Involve-ment of the Endocannabinoid System,” International Journal of Neuropsychopharmacology 16, no. 6 (2013): 1407–1419. doi:10.1017/S1461145712001502.

[312] McGill University, “Cannabis: Potent Anti-depressant In Low Doses, Worsens Depression At High Doses,” ScienceDaily, October 24, 2007.[313] M. N. Hill, C. J. Hillard, F. R. Bambico, S. Patel, B. B. Gorzalka, and G. Gobbi, “The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants,” Trends in Pharmacological Sciences 30, no. 9 (2009): 484–493. doi:10.1016/[314] R. Linge, L. Jiménez-Sánchez, L. Campa, F. Pilar-Cuéllar, R. Vidal, A. Pazos, and A. Adell Díaz, “Cannabidiol Induces Rapid-Acting Antidepressant-Like Effects and Enhances Cortical 5-HT/Glu-tamate Neurotransmission: Role of 5-HT1A Receptors,” Neuropharmacology 103 (2016): 16. doi:10.1016/j.neuropharm.2015.12.017.

[315] Samir Haj-Dahmane and Roh-Yu Shen, “Endocannabinoid Signaling and the Regulation of the Serotonin System,” in Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders, ed. Elisabeth J. Van Bockstaele (New York: Springer, 2013), 239–254. doi:10.1007/977-4614-7940-6_11.

[316] M. N. Hill, C. J. Hillard, F. R. Bambico, S. Patel, B. B. Gorzalka, and G. Gobbi, “The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants,” Trends in Pharmacological Sciences 30, no. 9 (2009): 484–493. doi:10.1016/

[317] C. H. Ashton, P. B. Moore, P. Gallagher, and A. H. Young, “Cannabinoids in Bipolar Affective Dis-order: A Review and Discussion of Their Therapeutic Potential,” Journal of Psychopharmacology 19, no. 3 (2005): 293–300.

[318] A. Zuardi, J. Crippa, S. Dursun, S. Morais, J. Vilela, R. Sanches, and J. Hallak, “Cannabidiol Was Ineffective for Manic Episode of Bipolar Affective Disorder,” Journal of Psychopharmacology 24, no. 1 (2010): 135– 137. doi:10.1177/0269881108096521.

[319] Abir T. El-Alfy, Kelly Ivey, Keisha Robinson, Safwat Ahmed, Mohamed Radwan, Desmond Slade, Ikhlas Khan, Mahmoud ElSohly, and Samir Ross, “Antidepressant-Like Effect of ∆9-tetrahydrocannab-inol and Other Cannabinoids Isolated from Cannabis sativa,” Journal of Pharmacology, Biochemistry and Behavior 95, no. 4 (June 2010): 434–442.

[320] A. R. de Mello Schier, N. P. de Oliveira Ribeiro, D. S. Coutinho, S. Machado, O. Arias-Carrión, J. A. Crippa, A. W. Zuardi, A. E. Nardi, and A. C. Silva, “Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa,” CNS Neurol Disorders – Drug Targets 13, no. 6 (2014): 953–960.

[321] Michael Moskowitz MD, personal communication with the authors, February 2, 2017.

[382] J. Russell Reynolds, “On Some of the Therapeutical Uses of Indian Hemp,” in Archives of Medi-cine, vol. 2 (London, 1859), 154.

[383] R. Greco, V. Gasperi, M. Maccarrone, and C. Tassorelli, “The Endocannabinoid System and Mi-graine,” Experimental Neurololgy 224, no. 1 (2010): 85–91. doi:10.1016/j.expneurol.2010.03.029.

[384] Ethan Russo and Andrea Hohmann, “Role of Cannabinoids in Pain Management,” in Compre-hensive Treatment of Chronic Pain by Medical, Interventional and Integrative Approaches, ed. Timo-thy R. Deer et al. (New York: Springer, 2013), 181–197.

[385] “Testimonials,” No High CBD Oil, last modifed March 8, 2017, http://

[386] E. B. Russo, “Cannabinoids in the Management of Diffcult to Treat Pain,” Journal of Therapeu-tics and Clinical Risk Management 4, no. 1 (2008): 245–259.

[387] S. Maione, F. Piscitelli, L. Gatta, D. Vita, L. De Petrocellis, E. Palazzo, V. de Novellis, and V. Di Marzo, “Non-psychoactive Cannabinoids Modulate the Descending Pathway of Antinociception in Anaesthetized Rats through Several Mechanisms of Action,” British Journal of Phramacology 162, no. 3 (2011): 584. doi:10.1111/j.1476-5381.2010.01063.x.

[388] W. Xiong, T. Cui, K. Cheng, F. Yang, S. R. Chen, D. Willenbring, Y. Guan, H. L. Pan, K. Ren, Y. Xu, and L. Zhang, “Cannabinoids Suppress Infammatory and Neuropathic Pain by Targeting Δ3 Gly-cine Receptors,” Journal of Experimental Medicine 209, no. 6 (2012): 1121–1134. doi:10.1084 /jem.20120242.

[389] M. DeGeorge, E. Dawson, P. Woster, L. Burke, and K. Bronstein, An Analysis of the Association between Marijuana Use and Potential Nonadherence in Patients Prescribed Hydrocodon (Baltimore: Ameritox, 2013), www.ameritox .com/wp-content/uploads/Ananalysisoftheassociationbetweenmari-jua nauseandpotentialnonadherence_AAPM2013.pdf.

[417] E. Murillo-Rodríguez, D. Millán-Aldaco, M. Palomero-Rivero, R. Mechoulam, and R. Druck-er-Colín, “The Nonpsychoactive Cannabis Constituent Cannabidiol Is a Wake-Inducing Agent,” Behav-ioral Neuroscience 122, no. 6 (2008): 1378–1382.

[418] Dr. Michael Moskowitz, personal communication with authors, October 2016

[419] D. W. Carley, S. Paviovic, M. Janelidze, and M. Radulovacki, “Functional Role for Cannabinoids in Respiratory Stability during Sleep,” Sleep 25, no. 4 (2002): 391–398. PubMed PMID: 12071539.

[420] Bharati Prasad, Miodrag G. Radulovacki, and David W. Carley, “Proof of Concept Trial of Dronab-inol in Obstructive Sleep Apnea,” Frontiers in Psychiatry 4 (2013): 1.

[421] E. B. Russo, G. W. Guy, and P. J. Robson, “Cannabis, Pain, and Sleep: Lessons from Therapeutic Clinical Trials of Sativex, a Cannabis-Based Medicine,” Chemistry and Biodiversity 4, no. 8 (2007): 1729–1743.

[422] M. H. N. Chagas, A. L. Eckeli, A. W. Zuardi, M. A. Pena-Pereira, M. A. Sobreira-Neto, E. T. Sobreira, M. R. Camilo, M. M. Bergamaschi, C. H. Schenck, J. E. C. Hallak, V. Tumas, and J. A. S. Crippa, “Canna-bidiol Can Improve Complex Sleep-Related Behaviours Associated with Rapid Eye Movement Sleep Behaviour Disorder in Parkinson’s Disease Patients: A Case Series,” Journal of Clinical Pharmacy and Therapeutics 39 (2014): 564–566. doi:10.1111/jcpt.12179.